Demographic, clinical, and virologic characteristics of African-born persons with HIV/AIDS in a Minnesota Hospital

AIDS Patient Care and STDs

Volumn 21, Issue 5, 2007, Pages 356-365

  Akinsete, Omobosola O ^a,d   Sides, Tracy ^b,c   Hirigoyen, Diane ^a   Cartwright, Charles ^a   Boraas, Christy ^c   Davey, Cynthia ^c   Pessoa Brandão, Luisa ^b   McLaughlin, Mary ^a   Kane, Ellen ^a   Hall, Jane ^a   Henry, Keith ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MINNESOTA DEPARTMENT OF HEALTH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; ARTICLE; CD4 LYMPHOCYTE COUNT; DEMOGRAPHY; EDUCATION PROGRAM; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMIGRANT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PHYLOGENY; RETROSPECTIVE STUDY; SEX RATIO; STRUCTURAL GENE; UNITED STATES;

ADOLESCENT; ADULT; AFRICA; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; EMIGRATION AND IMMIGRATION; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MINNESOTA; RETROSPECTIVE STUDIES; SEX DISTRIBUTION;

EID: 34249690037     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.0074     Document Type: Article

References (44)

1. UNAIDS and WHO. Report on the global HIV/AIDS epidemic update 2005. Geneva: UNAIDS, December 2005. 〈www.unaids.org〈 (Last accessed March 2006).
2. United Nations High Commission on Refugees. Available at: www.unhcr.org Accessed 4March 2006.
3. Refugee Health Program. Minnesota Department of Health. 〈www.health.state.mn.us〉 (Last accessed September 1, 2006).
4. United States Census Bureau. U.S. Census 2000 data. 〈www.census. gov〉 (Last accessed March 4, 2006).
5. Minnesota Department of Health, Annual HIV/AIDS Surveillance Report, 2005. 〈www.health.state.mn.us〉 (Last accessed April 2006).
6. Centers for Disease Control and Prevention HIV and AIDS Surveillance Report, 2005. 〈www.cdc.gov〉 (Last accessed March 2006).
7. Sides TL, Akinsete O, Henry K, Wotton JT, Carr PW, Bartkus J. HIV-1 subtype diversity in Minnesota. J Infect Dis 2005;192:37-45.
8. Akinsete O, Hirigoyen D, Cartwright C, Schut R, Kantor R, Henry K. K103N mutation in antiretroviral therapy (ART) naive African patients infected with HIV-1. Clin Inf Dis 2004; 39:575-578.
9. Achkar J, Burda S, Konings F, et al. Infection with HIV type 1 group M non-B subtypes in individuals living in New York city. J Acquir Immune Defic Syndr 2004;36:835-843.
10. Jenny-Atival ER, Beatrice ST. Erroneously low or undetectable plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid load, determined by polymerase chain reaction, in West African and American patients with non-B subtype HIV-1 infection. Clin Infect Dis 2001; 32:1227-1230.
11. Sullivan PS, Do AN, Ellenberger D, et al. Human immunodeficiency virus (HIV) subtype surveillance of African-born Persons at pisk for group O and group N HIV infections in the United States. J Infect Dis 2000;181:463-469.
12. McMunn AM, Mwanje R, Pozniak AL. Issues facing Africans in London with HIV infection. Genitourin Med 1997;73:157-158.
13. Staehelin C, Rickenbach M, Low N, et al., for the Swiss HIV Cohort Study. Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: Access to antiretroviral therapy, disease progression and survival. AIDS 2003;17: 2237-2244.
14. Sinka K, Mortimer J, Evans B, Morgan D. Impact of the HIV epidemic in sub-Saharan Africa on the pattern of HIV in the UK. AIDS 2003;17:1683-1690.
15. Nellen JF, Wit FW, de Wolf F, Jurrianns, Lange JM, Prins JM. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and non-indigenous HIV-1-infected patients in the Netherlands. J Acquir Immune Defic Syndr 2004;36:943-950.
16. Del Amo J, Boring G, Fenton K. HIV health experiences among migrant Africans in Europe: How are we doing? AIDS 2003;17:2261-2263.
17. Couturier E, Damond F, Roques P, et al. HIV-1 diversity in France, 1996-1998. The AC 11 laboratory network. AIDS 2000;14:289-296.
18. Burns FM, Fakoya AO, Copas AJ, French PD. Africans in London continue to present with advanced HIV disease in the era of highly active antiretroviral therapy. AIDS 2001;15:2453-2455.
19. Del Amo, Petruckevitch A, Phillips A. Johnson AM, et al. Disease progression and survival in HIV-1-infected Africans in London. AIDS 1998;12:1203-1209.
20. Guidelines for the use of antiretroviral agents in HIV-infected Adults and adolescents, 2004. 〈www.aidsinfo.nih.gov〉 (Last accessed August 6, 2004).
21. Kuritzkes DR, Grant RM, Feorino P, et al., Performance characteristics of the TRUGENE HIV-1 genotyping kit and the opengene DNA sequencing system. J Clin Microbiol 2003;41:1594-1599.
22. Hirigoyen D, Cartwright C. Recognition and characterization of non subtype-B human immunodeficiency virus type 1 strains using sequence data generated in the Bayer tru-gene genotyping assay. J Clin Microbiol 2005;42:5263-5271.
23. 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with HIV. United States Public Health Service and Infectious Disease Society of America, November 28, 2001. 〈www.aidsinfo. nih.gov〉 (Last accessed March 2006).
24. Nakyonyi MM. HIV/AIDS Education Participation by the African Community. Can J Public Health 1993;84(Suppl 1):S19-23.
25. Castilla J, Sobrino P, De La Fuente L, Noguer I, Guerra L, Parras F. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: Consequences for AIDS incidence. AIDS 2002;16:1945-1951.
26. Rosenthal L, Scott D, Kelleta Z, et al. Assessing the HIV/AIDS health services needs of African Immigrants to Houston. AIDS Educ Prev 2003;15:570-580.
27. Halperin DT, Epstein H. Concurrent sexual partnerships help to explain Africa's high HIV prevalence: Implications for prevention. Lancet 2004;364:4-6.
28. Worth H, Denholm N, Bannister J. HIV/AIDS and the African refugee education program in New Zealand. AIDS Educ Prev 2003;15:346-356.
29. Smith AMA, de Visser R, Akande A, Rosenthal D, Moore S. Australian and South African undergraduates' HIV-related knowledge, attitudes, and behaviors. Arch Sex Behav 1998;27:279-293.
30. Fenton KA, Chinouya M, Davidson O, Copas A, MAYISHA study team. HIV testing and high risk behavior among London's migrant African communities: A participatory research study. Sex Transm Infect 2002;78:241-245.
31. Badri M, Ehrlich R, Wood R, Pulerwitz T, Maartens G. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area Intl J Tuberculosis Lung Dis 2001;5:225-232.
32. Kempainen R. Mycobacterium tuberculosis disease in Somali immigrants in Minnesota. Chest 2001;119:176-180.
33. Rock RB, Mills W, Williams D. Extrapulmonary Tuberculosis among Somali Immigrants in Minnesota [Abstract 414]. Presented at: Infectious Disease Society of America conference. San Diego, CA: 2003.
34. Tatt ID, Barlow KL, Nicoll A, Clewley JP. The public health significance of HIV-1 subtypes. AIDS 2001;15(Suppl 5):S59-71.
35. Osmanov S, Pattou C, Walker N, et al. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2000;29:184-190.
36. Fenton KA, Chinouya M, Davidson O, Copas A. HIV transmission risk among sub-Saharan Africans in London traveling to their countries of origin. AIDS 2001;15:1442-1445.
37. Treadwell TL, Fleisher J. Underestimation of HIV-1 plasma viral burden in patients who acquire infection abroad: The experience in a community hospital clinic. Arch Intern Med. 2003;163:1613-1614.
38. Gottesman BS, Grossman Z, Lorber M, et al. Measurement of HIV RNA in patients infected by subtype C by assays optimized for subtype B results is an underestimation of the viral load. J Med Virol 2004;73:167-171.
39. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a Global Collaboration. PLoS Med (serial online). April 2005;2(4):e112. 〈http://medicine.plosjournals.org〉 (Last accessed November 2005).
40. Alexander CS, Montessori V, Wynhoven B, et al. Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir Ther 2002;7:31-35.
41. Bocket L, Cheret A, Deuffic-Burban S, et al. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther 2005;10:247-254.
42. Fleury HJ, Thomas T, Lan NTH, et al. Susceptibility to antiretroviral drugs to CRF01-AE, CRF02-AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data. AIDS Res Hum Retriviruses 2006;22:357-366.
43. Liu H, Hu Z, Li X, Stanton B, Naar-king S, Yang H. Understanding interrelationships among HIV-related stigma, concern about HIV infection and intent to disclose HIV serostatus: A pretest/posttest study in a rural area of eastern China. AIDS Patient Care STDs 2006;20:133-142.
44. Brooks RA, Etzel MA, Hinijos E, Henry CL, Perez M. Preventing HIV among Latino and African American gay and bisexual men in a context of HIV-related stigma, discrimination, and homophobia: Perspectives of providers. AIDS Patient Care STDs 2005;19:737-744.